Graig Suvannavejh
Stock Analyst at Mizuho
(2.21)
# 2,512
Out of 4,817 analysts
142
Total ratings
41.12%
Success rate
-7.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $29.55 | +11.68% | 8 | Apr 7, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $7 | $4.93 | +41.99% | 6 | Apr 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $216 | $103.99 | +107.71% | 21 | Mar 27, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $44 | $29.18 | +50.79% | 17 | Mar 18, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.26 | +476.70% | 2 | Nov 27, 2024 | |
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $1.59 | +377.99% | 1 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $17.37 | +118.83% | 6 | Oct 24, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $6.67 | +1,009.45% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.26 | +90.11% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $58.15 | -15.74% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $18.64 | +168.24% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.71 | +2,717.70% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $71.16 | +15.23% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $4.35 | +268.24% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $6.48 | +363.32% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $2.96 | +644.50% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $1.39 | +475.54% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $3.32 | +5.42% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $2.80 | +257.14% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.10 | +718.18% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.68 | +3,709.52% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.51 | -60.16% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.84 | +715.22% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $59.28 | -40.96% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.67 | +117.98% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $37.81 | +50.75% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $37.99 | -86.84% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.81 | +399.27% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.95 | +609.76% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $13.58 | +128.36% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.70 | +2,627.93% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.96 | +142.35% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $13.83 | +160.30% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $25.01 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.94 | +3,841.62% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $103.38 | +23.82% | 1 | Sep 14, 2020 |
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $29.55
Upside: +11.68%
Amylyx Pharmaceuticals
Apr 7, 2025
Upgrades: Outperform
Price Target: $3 → $7
Current: $4.93
Upside: +41.99%
Axsome Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $103.99
Upside: +107.71%
Harmony Biosciences Holdings
Mar 18, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $29.18
Upside: +50.79%
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.26
Upside: +476.70%
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.59
Upside: +377.99%
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $17.37
Upside: +118.83%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $6.67
Upside: +1,009.45%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.26
Upside: +90.11%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $58.15
Upside: -15.74%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $18.64
Upside: +168.24%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.71
Upside: +2,717.70%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $71.16
Upside: +15.23%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $4.35
Upside: +268.24%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $6.48
Upside: +363.32%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $2.96
Upside: +644.50%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.39
Upside: +475.54%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $3.32
Upside: +5.42%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $2.80
Upside: +257.14%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.10
Upside: +718.18%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.68
Upside: +3,709.52%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.51
Upside: -60.16%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $1.84
Upside: +715.22%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $59.28
Upside: -40.96%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.67
Upside: +117.98%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $37.81
Upside: +50.75%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $37.99
Upside: -86.84%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $6.81
Upside: +399.27%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.95
Upside: +609.76%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $13.58
Upside: +128.36%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.70
Upside: +2,627.93%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.96
Upside: +142.35%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $13.83
Upside: +160.30%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $25.01
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.94
Upside: +3,841.62%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $103.38
Upside: +23.82%